Infectious diseases caused by bacteria, such as Yersinia enterocolitica, pose significant global health challenges. Y. enterocolitica, a Gram-negative bacterium, is known for causing gastrointestinal diseases in humans. The objective of this study was to identify potential drug targets to combat Yersinia enterocolitica infection. Using subtractive genomics, pan-genome analysis was performed on 23 complete genomes of Y. enterocolitica, resulting in 3025 core genes. Using VacSol, 2267 non-host homologous proteins were identified, and 29 essential proteins were identified using the Database of Essential Genes (DEG). Moreover, from these essential genes, nine cytoplasmic proteins were acquired based on topology, modeled, and analyzed for their druggability using Swiss Model, AutoDock Vina, and Galaxy Refine tools. Furthermore, these proteins were docked with 30 fluoroquinolone compounds, which revealed several promising interactions. Notably, the Two-component system response regulator OmpR showed strong interactions with ciprofloxacin, whereas the large ribosomal subunit protein uL13 demonstrated significant binding with nalidixic acid. Phosphoheptose isomerase and protein-export protein SecB exhibited potential with norfloxacin and ciprofloxacin, respectively. These findings indicated that these proteins are viable targets for drug development against Y. enterocolitica. The increasing antibiotic resistance of Y. enterocolitica highlights the urgent need for novel therapeutic strategies, making these insights crucial for future drug development.